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Abstract
Aims and background. RARE-Bestpractices is a four-year European collaborative project that has as 
one of its primary goals the facilitation of global access to trustworthy guidelines on rare diseases. This 
paper describes the findings of a workshop held with representatives of ten RARE-Bestpractices partner 
organisations to explore the utility of the AGREE-II instrument for the quality appraisal of rare disease 
guidelines.
Methods. Participants viewed the online AGREE-II overview tutorial and worked in small groups to com-
plete appraisals of two guidelines on Huntington’s disease. Participants discussed their views on using 
the instrument to appraise rare disease guidelines.
Results and discussion. All domains and items of the AGREE-II instrument were considered relevant 
to appraising the quality of the selected guidelines; additionally, it was possible to identify information 
within the guidelines to support a judgment on the score for each item. Discussion on areas of difficulty 
or disagreement has resulted in a set of notes on how to address problems of interpretation that may 
commonly be encountered when applying AGREE-II to rare disease guidelines. 
Conclusion. The AGREE-II instrument is applicable regardless of the small patient numbers, potentially 
small volume of evidence, and other limitations typically encountered in rare disease guidelines.
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Introduction
RARE-Bestpractices is a four year collaborative project funded by the European 
Union Seventh Framework Programme. One of the primary goals of the project is to 
promote and facilitate communication on the management of rare diseases by facili-
tating global access to, and dissemination of, trustworthy guidelines on rare diseases. 
To this end an online database of guidelines, on topics ranging from diagnosis and 
treatment to the organisation of care, is being developed by RARE-Bestpractices part-
ners to provide professionals, patients and policy makers with robust and up to date 
information on the care of individuals with rare diseases [1].
A previous study by members of the RARE-Bestpractices project explored the utility 
of existing databases for identifying guidelines on rare diseases. Based on a low search 
yield for three rare conditions in the largest two guideline specific databases the authors 
concluded that rare disease guidelines may not be well represented in existing databases 
and provided a novel search strategy for their identification [2]. This approach to iden-
tification of rare disease guidelines is being used to retrieve guidelines on a range of rare 
conditions for inclusion in the RARE-Bestpractices guideline database.
Following identification of guidelines, an assessment of their methodological qual-
ity is required to ensure that the most robust and trustworthy guidelines can be high-
lighted. A systematic review identified 40 tools for appraisal of guideline quality [3] 
with the most comprehensively validated of these being the Appraisal of Guidelines 
for Research & Evaluation (AGREE II, http://www.agreetrust.org/). 
The AGREE II instrument is an internationally recognised assessment tool which con-
sists of 23 items arranged into six quality domains [4, 5]. Each domain represents a 
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organisations and policy makers were represented. 
As an introduction to the AGREE II instrument the par-
ticipants watched the AGREE II Overview Tutorial (http://
www.agreetrust.org/resource-centre/agree-ii-training-
tools). This tutorial provides an avatar-guided overview of 
the AGREE II instrument, briefly describing each of the 
items from the six quality domains and introducing how 
the scoring should be conducted.
Following a preliminary discussion of potential issues 
that could arise in the use of the AGREE II instrument for 
appraising rare disease guidelines, participants formed 
four groups to simultaneously conduct an appraisal of a 
guideline on nutritional management for Huntington’s 
disease [8]. To provide further experience in using the 
AGREE II instrument, a second guideline, on the pharma-
cological management of chorea in Huntington’s disease 
[9] was then appraised.
The two guidelines were chosen pragmatically from 
those identified in a previous study [2] as examples that 
covered drug and non-drug interventions, and that pro-
vided sufficient information to support informed judge-
ment on most if not all AGREE items. Within the time 
limitations of the workshop, only two guideline apprais-
als could be completed.
Results and discussion
The first appraisal took approximately 90 minutes to 
complete. Ratings for overall quality, which summarise 
the methodological assessment,  ranged from 1 to 3 (on 
a scale of 1-7 where seven indicates highest quality).Three 
of the four groups recorded that they would, despite this 
low quality-score, recommend the guideline with modifi-
cations, with one group not reaching consensus on a judge-
ment.
The workshop participants then discussed issues arising 
in the application of the AGREE II instrument. There was 
variation both within and among groups in the scores 
assigned. This was particularly apparent for items within 
unique dimension of guideline quality, and from the item 
scores (range 1-7) a quality score for each domain is cal-
culated.
The six domain scores are judged as independent factors 
and so cannot be aggregated into a single quality score. 
Overall guideline quality is a separate judgement based 
on the assessment process as a whole and is considered 
alongside the question of whether the appraiser would 
recommend the guideline for use, for use with modi-
fications or would not recommend use. It is suggested 
that each guideline is assessed by at least two appraisers 
(preferably four), in order to increase the reliability of the 
assessment [6]. Practical application of the AGREE II in-
strument includes its use as the basis of the guidance ac-
creditation process of the National Institute of Health and 
Care Excellence [7].
This article reports on an international workshop deliv-
ered by the RARE-Bestpractices partners which aimed to:
•	 provide	 participants	 with	 experience	 of	 using	 the	
AGREE II instrument in a multidisciplinary environ-
ment;
•	 stimulate	discussion	on	appraisal	of	rare	disease	guide-
lines, and from this, develop an informal consensus on 
the utility of the AGREE II instrument for appraising 
rare disease guidelines within the context of the RA-
RE-Bestpractices database.
Methods
With a view to specifying AGREE II appraisals as a fea-
ture of the RARE-Bestpractices guideline database, mem-
bers of the RARE-Bestpractices consortium were invited to 
participate in a two-day workshop to explore the utility 
of this instrument for appraisal of rare disease guidelines. 
The workshop took place in Edinburgh, Scotland in Octo-
ber 2014. The employing organisation and geographic lo-
cation of participants are described in Table 1. There were 
13 participants. Clinicians, guideline developers, patient 
Table 1. Organisations participating in the guideline evaluation workshop
Organisation Location
DEBRA Ireland Dublin, Ireland
The European Academy of Paediatrics Bruxelles, Belgium
EURORDIS, European Organisation for Rare Diseases Paris, France
Fundación Canaria de Investigación y Salud Las Palmas de Gran Canaria, Spain
Healthcare Improvement Scotland Glasgow, UK
The Children’s Hospital at Westmead and The University of Sydney Sydney, Australia
Istituto Superiore di Sanità Rome, Italy
University of Maastricht Maastricht, The Netherlands
Murdoch Children’s Research Institute Melbourne, Australia
Newcastle University Upon Tyne Newcastle, UK
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mended the guideline for use with modifications despite 
a low quality score. This discrepancy related to the value 
placed on a guideline that was unique in addressing its 
topic and reluctance to reject it in the absence of other 
guidelines. Later in the workshop the view that guidelines 
should not be categorised as ‘recommended for use’ sim-
ply because there are few available was emphasised within 
the group. Secondly, although it may be challenging to 
achieve, participation of patients and their carers or repre-
sentatives is viewed as vital for the development of a high 
quality rare disease guideline.
The second appraisal took approximately 40 minutes to 
complete with groups assigned specific domains within 
the AGREE II instrument for more detailed consideration 
of the application of each domain in the context of a rare 
disease guideline. No overall quality rating was made due 
to the domains being allocated across the participants. 
The participant pairs were then invited to present to the 
whole group a detailed discussion of the application of 
the AGREE II items in light of their growing experience 
of using the tool in the context of rare disease guidelines. 
Following completion of the second guideline apprais-
al, participants concluded that the AGREE II instrument 
is appropriate for evaluation of rare disease guidelines 
but that some notes to supplement the AGREE II man-
ual should be developed to support appraisals of rare 
the ‘rigour of development’ and ‘editorial independence’ 
domains. These variations arose both from differences in 
the interpretation of the methodological descriptions in 
the AGREE II guidance document and from identification 
or interpretation of material within the guideline being 
examined. 
Other issues related to scoring of the AGREE II items 
highlighted by workshop participants included:
•	 judgement	 ‘generosity’	 can	 be	 influenced	 by	 mood,	
context and appraisal workload;
•	 information	within	the	guidelines	is	not	always	easy	to	
find so appraisal can be a time consuming process;
•	 knowledge	of	the	rare	disease	can	influence	the	apprais-
al rating given a clinical subject expert may identify 
quality issues not apparent to non experts;
•	 although	 for	 some	 items	 there	was	wide	 variation	 in	
scores, the overall quality judgement was consistently 
low across the groups.
Two principles were emphasised and agreed by the 
group. Firstly, it is as important that guidelines for rare 
diseases are high quality as it is for guidelines for com-
mon conditions; therefore quality standards should not 
be lowered for rare disease guidelines. Paradoxically, how-
ever, the three groups who recorded a judgement recom-
Table 2. Notes on use of the AGREE II instrument for guideline quality evaluation in rare diseases
AGREE II Domain Points to consider
Scope and purpose
(Items 1-3)
Rare disease guidelines should be able to address all of the items concerned with scope and purpose. 
Stakeholder involvement
(Items 4-6)
Although it is likely that one professional group may dominate, comprehensive stakeholder involvement  
is as important to the development of guidelines for rare diseases as it is for common diseases.
Scoring of these items should recognise this principle and reflect the extent to which the guideline addresses  
each item.
Rigour of development
(Items 7-14)
The AGREE II quality rating does not depend on the quantity or type of published evidence but on the rigour of the 
systematic methods used to identify, select and synthesise evidence and the transparency with which the guideline 
development group report how they reached recommendations. 
For item 13 (external review by experts) – the experts should include patients, carers, and/or patient groups.
Clarity of presentation
(Items 15-17)
When scoring item 16 there may not be a range of options for management of the (rare) condition or health issue.  
In this case the item would be considered ‘not applicable’ and scored as ‘1’.
Applicability
(Items 18-21)
The extent to which a guideline can provide information on potential facilitators to guideline implementation  
and describe resource implications may be limited for rare disease guidelines where the implementation setting  
is likely to encompass diverse healthcare contexts.
The information provided may be country-specific, healthcare system-specific, or generic.
Editorial independence
(Items 22-23)
For many rare diseases there are likely to be only a small number of experts worldwide. This may limit the potential  
for editorial independence. Scores should reflect how this was addressed.
Overall guideline assessment Before selecting ‘yes with modifications’, consider whether resources are available to modify the guideline and any 
copyright issues. 
The existence of only a few or only one guideline on a topic should not prevent a judgment of ‘no’ on question 2 as it is 
worthwhile to indicate that better quality guidelines are needed. 
Notes section Indicate if the guideline is the only (known) guideline on available on the topic.
Indicate any research recommendations which the guideline identifies.
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disease guidelines. Discussion focused on the particular 
items of AGREE II where difficulty or disagreement was 
experienced and additional notes for appraisers was de-
veloped from these points as summarised in Table 2. It is 
intended that these notes will be used and further refined 
during the course of the project as a wider community of 
researchers and clinicians apply the AGREE II tool in prac-
tice, while building the repository of appraised guidelines.
Conclusions
One of the key objectives of the RARE-Bestpractices 
project is to support the development and global dissem-
ination of trustworthy guidelines for the management of 
rare conditions. It was recognised early in the project that 
establishing a process for appraising guidelines was essen-
tial as not all guidelines, for rare or common conditions, 
are of equal quality [10].
The workshop described here was designed to test a 
method for undertaking this quality assessment and has 
demonstrated that use of the AGREE II instrument is fea-
sible for the appraisal of the methodological quality of 
rare disease guidelines. During the course of testing the 
AGREE II instrument specific challenges relating to the 
appraisal of rare disease guidelines were identified and 
supplementary notes have been produced to support 
quality assessment of these guidelines. 
As a report of an exploratory workshop, this study inev-
itably has limitations. The workshop was designed to test 
the feasibility of the AGREE II quality appraisal tool and 
to enable discussion of the broader issues around quality 
assessment for rare disease guidelines. It employed nei-
ther formal qualitative research methods nor formal con-
sensus methods. It is further limited in exploring only one 
appraisal tool and testing this tool on only two guidelines 
due to time limitations. However, this study does repre-
sent a step towards further research into the quality ap-
praisal of rare disease guidelines and may stimulate those 
developing guidelines for care and treatment of individu-
als with rare diseases to consider methodological aspects 
associated with guideline quality.
The supplementary notes provide clarification on scor-
ing of some AGREE II items, such as the potential lack 
of a range of available treatment options or a paucity of 
experts on the condition. The notes emphasise that items 
in the ‘rigour of development’ domain are applicable re-
gardless of the number of people affected (few), volume 
of published evidence (potentially small), type of studies 
(randomised or non-randomised) or number of existing 
guidelines (potentially few). The AGREE II instrument and 
additional notes will be integrated into the RARE-Bestprac-
tices guidelines database providing patients, clinicians, and 
policy makers with a detailed assessment of the quality of 
the methodology used to develop the guideline. The project 
aims to recruit between two and four appraisers for each 
guideline in the collection. 
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